UHRF1 and cancer: When both cohorts were analyzed together, we confirmed the prevalence of higher DNMT1, G9a, and UHRF1 immunostaining scores (score 3 +) in cancer cells compared to normal ducts, in which lower levels (score 0, 1 + , and 2 +) were more prevalent.